Every material Form 8-K Cigna filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
The Cigna Group reported third quarter 2025 results (three months ended September 30). Total revenues rose 10% to $69.7 billion, and shareholders' net income was $1.9 billion, or $6.98 per share, compared with $0.7 billion, or $2.63 per share, a year earlier, which included a one-time $1.0 billion after-tax investment loss. The company reaffirmed its full-year 2025 adjusted income from operations outlook of at least $29.60 per share, which matters to shareholders because it signals management's expectations for the year.
Total revenues were $69.7 billion, up 10% from $63.7 billion in Q3 2024, driven mainly by Evernorth Health Services.
Shareholders' net income was $1.9 billion, or $6.98 per share, versus $2.63 per share in Q3 2024.
Adjusted income from operations was $2.1 billion, or $7.83 per share, versus $7.51 per share in Q3 2024; in dollar terms it fell 1%.
Full-year 2025 adjusted EPS outlook reaffirmed at least $29.60; Cigna Healthcare medical care ratio was 84.8% in Q3, up from 82.8%.
Cigna Group said retired Major General Elder Granger, M.D. informed its Board on October 15, 2025 that he will retire as a director effective December 31, 2025. The company said the retirement follows its Board retirement age policy and is not the result of any disagreement with the company.
Elder Granger, M.D. will retire from the Cigna Board effective December 31, 2025.
He notified the Board on October 15, 2025.
The company said the retirement is consistent with the Board's retirement age policy and not due to any disagreement.
Cigna completed a $4.5 billion sale of four series of senior notes maturing from 2030 to 2056. The company said it will use most of the proceeds to repay $2.0 billion of loans under a term loan that funded a strategic investment in another company.
Four note series totaling $4.5 billion: $1.0 billion due 2030, $1.25 billion due 2032, $1.5 billion due 2036, and $750 million due 2056
Proceeds to repay $2.0 billion outstanding under the Term Loan Agreement dated August 5, 2025; remainder for general corporate purposes
Interest rates range from 4.500% to 6.000%, with the 2056 notes carrying the highest rate
The Cigna Group reported second quarter 2025 total revenues of $67.2 billion, up 11% from a year earlier, and shareholders' net income of $1.5 billion, or $5.71 per share, compared with $5.45 per share in the second quarter of 2024. The company reaffirmed its full-year 2025 adjusted income from operations outlook of at least $29.60 per share, while adjusted income from operations at Cigna Healthcare fell 9% on higher medical costs.
Total revenues were $67.2 billion, up 11% from $60.5 billion in the second quarter of 2024.
Shareholders' net income was $1.5 billion, or $5.71 per share, versus $5.45 per share a year earlier.
Adjusted income from operations was $1.9 billion, or $7.20 per share, versus $6.72 per share; full-year 2025 outlook of at least $29.60 per share was reaffirmed.
Cigna Healthcare adjusted pre-tax income fell 9% to $1.1 billion, driven mainly by a medical care ratio of 83.2% versus 82.3%.
The Cigna Group appointed Michael J. Hennigan as an independent director, effective June 2, 2025, with the board approving the appointment on May 30, 2025. Hennigan is Executive Chairman of Marathon Petroleum and MPLX, a board addition with an energy-industry background that does not change the company's reported financial results.
Board appointed Michael J. Hennigan on May 30, 2025; his appointment is effective June 2, 2025.
Hennigan is Executive Chairman of Marathon Petroleum Corporation and MPLX and previously served as CEO of both.
He will join the non-employee director compensation program, as described in the 2025 proxy statement filed March 14, 2025.
Cigna will file an amended Form 8-K to disclose his committee assignments once determined.
The Cigna Group reported first quarter 2025 results, with total revenues up 14% to $65.5 billion and shareholders' net income of $1.3 billion, or $4.85 per share, compared with a net loss a year earlier. The company raised its full-year 2025 adjusted income from operations outlook to at least $29.60 per share, up $0.10, which supports earnings expectations for shareholders.
Total revenues rose 14% to $65.5 billion; shareholders' net income was $1.3 billion, or $4.85 per share, versus a $0.3 billion loss ($0.97 per share) in Q1 2024.
Adjusted income from operations was $1.8 billion, or $6.74 per share, compared with $6.47 per share in Q1 2024.
Cigna Healthcare adjusted pre-tax income fell 4% to $1.3 billion, with the medical care ratio rising to 82.2% from 79.9%.
The company completed the sale of its Medicare businesses to HCSC on March 19, 2025, and repurchased 8.2 million shares for about $2.6 billion year to date through May 1, 2025.
Cigna entered a $6.5 billion five-year revolving credit agreement dated April 24, 2025, which replaces its existing revolving facilities and terminates its $5.0 billion agreement dated April 25, 2024. Separately, Executive Vice President and Global Chief Information Officer Noelle Eder resigned effective May 16, 2025, for personal reasons, and shareholders at the April 23, 2025 annual meeting elected all eleven director nominees.
New $6.5 billion revolving credit agreement, dated April 24, 2025, for general corporate purposes, with up to $500 million for letters of credit and options to increase commitments by up to $1.5 billion
Leverage ratio covenant of 0.60 to 1.00, or 0.65 to 1.00 for four quarters after an acquisition with cash consideration of $1.0 billion or more
Noelle Eder resigned as EVP and Global Chief Information Officer, effective May 16, 2025, with no disagreement with the company cited
At the annual meeting, 91.04% of shares were represented; a shareholder proposal on special shareholder meetings received 28,117,178 votes for and 200,491,789 against
Cigna Group said Eric P. Palmer, Executive Vice President for Enterprise Strategy and President and Chief Executive Officer of Evernorth Health Services, will leave the company on April 26, 2025. Under an agreement signed April 15, 2025, he will receive a $5.2 million cash payment and continued vesting of certain equity awards, which the company estimates at about $4.8 million. The filing does not give a reason for the departure or name a successor.
Employment ends April 26, 2025; Palmer is EVP for Enterprise Strategy and President and CEO of Evernorth Health Services
Cash payment of $5.2 million, including 78 weeks of base pay and 150% of his 2025 EIP target
Equity treatment estimated at about $4.8 million, based on the April 15, 2025 closing price of $328.63 per share
Stock options granted before 2021 expire on the lesser of their original date or 90 days after April 26, 2025
Cigna Group announced leadership changes effective March 31, 2025: Brian C. Evanko becomes President and Chief Operating Officer, and Ann M. Dennison becomes Executive Vice President and Chief Financial Officer. The company also reaffirmed its 2025 adjusted income from operations outlook of at least $29.50 per share, which matters to shareholders because it signals no change to prior guidance alongside a senior management reshuffle.
Evanko's effective base salary is $1,100,000, with a 2025 EIP annual target of $2,200,000 and a 2026 LTI target of $6,700,000.
Dennison's effective base salary is $800,000, with a 2025 EIP annual target of $1,100,000 and a 2026 LTI target of $3,500,000, plus a 2025-2027 transitional strategic performance share grant valued at $750,000.
Eric P. Palmer's employment as EVP for Enterprise Strategy and CEO of Evernorth Health Services ends April 26, 2025; separation terms will be reported separately.
Cigna reaffirmed 2025 adjusted income from operations of at least $29.50 per share, Evernorth pre-tax adjusted income of at least $7.2 billion, and Cigna Healthcare pre-tax adjusted income of at least $4.1 billion.
The Cigna Group reported fourth quarter and full-year 2024 results on January 30, 2025. Full-year revenue rose 27% to $247.1 billion and adjusted income rose 4% to $7.7 billion, but fourth-quarter adjusted income fell 8% on higher stop loss medical costs at Cigna Healthcare, and GAAP net income fell to $3.4 billion from $5.2 billion after a $2.7 billion VillageMD impairment. The company projects 2025 adjusted income of at least $7.9 billion, or $29.50 per share, and raised its quarterly dividend 8% to $1.51 per share.
Q4 2024 shareholders' net income was $1.4 billion ($5.13 per share), versus $1.0 billion ($3.49 per share) in Q4 2023; Q4 adjusted income was $1.8 billion ($6.64 per share), versus $2.0 billion ($6.79 per share).
Full-year 2024 shareholders' net income of $3.4 billion ($12.12 per share) included a non-cash after-tax loss of $2.7 billion ($9.53 per share) tied to the VillageMD impairment.
2025 adjusted income from operations is projected at least $7.9 billion, or at least $29.50 per share.
Quarterly dividend raised 8% to $1.51 per share, payable March 20, 2025; total share repurchase authorization is $10.3 billion after a $6.0 billion increase.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cigna filing is on SEC EDGAR ↗. 8-K briefs of other companies →